Internal Medicine UnitRheumatologyDepartment of Internal Medicine and Medical SpecialtiesDepartment of OphthalmologyEndocrinology and DiabetesDepartment of Experimental Medicine, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.
Internal Medicine UnitRheumatologyDepartment of Internal Medicine and Medical SpecialtiesDepartment of OphthalmologyEndocrinology and DiabetesDepartment of Experimental Medicine, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy
Eur J Endocrinol. 2016 Feb;174(2):187-92. doi: 10.1530/EJE-15-0791. Epub 2015 Nov 17.
Osteopontin (OPN) is a sialoprotein implicated in different immunity and metabolic pathways. Capable of activating dendritic cells and inducing Th1-Th17-mediated tissue damage, OPN plays a significant role in the development/progression of several autoimmune diseases; interestingly, it was also shown that OPN participates in the acute pancreatic islets response to experimentally induced diabetes in non-obese diabetic (NOD) mice. Furthermore, OPN promotes adipose tissue dysfunction, systemic inflammation and insulin resistance. Our aims of this study were to evaluate circulating OPN levels in adult patients with type 1 diabetes mellitus (T1DM) compared to non-diabetic control participants and to unravel clinical and biochemical correlates of OPN concentration.
Case-control study.
We enrolled 54 consecutive T1DM patients referred to our diabetes outpatient clinic at Sapienza University of Rome and 52 healthy sex and age-comparable controls. The study population underwent clinical evaluation, blood sampling for biochemistry and complete screening for diabetes complications. Serum OPN levels were measured by MILLIPLEX Multiplex Assays Luminex.
T1DM patients had significantly higher serum OPN levels than controls (17.2±12.9 vs 10.5±11.6 mg/ml, P=0.009). OPN levels correlated with T1DM, higher blood pressure, BMI, creatinine, γ-GT, ALP and lower HDL; the association between high OPN levels and T1DM was independent from all confounders. No correlation was shown between OPN and HbA1c, C-peptide, insulin requirement, co-medications and diabetes duration.
This study demonstrates for the first time in a case-control study that adults with T1DM have increased serum OPN levels, and that higher OPN concentrations are associated with an unfavorable metabolic profile in these patients.
骨桥蛋白(OPN)是一种参与不同免疫和代谢途径的唾液酸糖蛋白。OPN 能够激活树突状细胞并诱导 Th1-Th17 介导的组织损伤,在几种自身免疫性疾病的发展/进展中发挥重要作用;有趣的是,还表明 OPN 参与了非肥胖型糖尿病(NOD)小鼠实验诱导的糖尿病对急性胰腺胰岛的反应。此外,OPN 促进脂肪组织功能障碍、全身炎症和胰岛素抵抗。我们本研究的目的是评估 1 型糖尿病(T1DM)成年患者与非糖尿病对照组相比循环 OPN 水平,并揭示 OPN 浓度的临床和生化相关性。
病例对照研究。
我们招募了 54 名连续的 T1DM 患者,这些患者来自罗马 Sapienza 大学的糖尿病门诊,并招募了 52 名性别和年龄匹配的健康对照组。研究人群接受了临床评估、血液生化采样和糖尿病并发症的全面筛查。通过 MILLIPLEX Multiplex Assays Luminex 测定血清 OPN 水平。
T1DM 患者的血清 OPN 水平明显高于对照组(17.2±12.9 与 10.5±11.6 mg/ml,P=0.009)。OPN 水平与 T1DM、更高的血压、BMI、肌酐、γ-GT、ALP 和更低的 HDL 相关;OPN 水平与 T1DM 之间的关联独立于所有混杂因素。OPN 与 HbA1c、C 肽、胰岛素需求、合并用药和糖尿病病程之间无相关性。
本病例对照研究首次证明,T1DM 成人的血清 OPN 水平升高,并且这些患者中较高的 OPN 浓度与不利的代谢谱相关。